Mail

"It is disingenuous, at best, to infer that the WARF patents are part of a "racket," which suggests that these patents may be illegal. They are not." Stem cell patent wars Re: "End this Stem Cell Racket"1 and "Working with Stem Cells? Pay Up"2: The novelty of claim one in Thompson's (WARF) patent is not in parts (i) through (iii), but in the final clause: "is inhibited from differentiation when cultured on a fibroblast feeder layer." Is it not possible to inhibit

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Re: "End this Stem Cell Racket"1 and "Working with Stem Cells? Pay Up"2: The novelty of claim one in Thompson's (WARF) patent is not in parts (i) through (iii), but in the final clause: "is inhibited from differentiation when cultured on a fibroblast feeder layer." Is it not possible to inhibit from differentiation using other techniques than a fibroblast feeder layer (e.g., see US Patent No. 6,800,480)? New approaches such as this one have been addressed not only because of Thompson's '806 patent, but because of the presence of impurities (such as viruses) in the feeder cells. If the non-feeder cell techniques do not work and using a fibroblast feeder layer is truly novel, then the patent is probably worth its reputed $400,000 license.

Further, the patent covers cells isolated from the blastocyst stage; cells derived either prior to or after the blastocyst stage may not be covered. For a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies